Although the EGFR tyrosine kinase inhibitors gefitinib and erlotinib have revolutionized the treatment of lung cancers, only patients with activating mutations of the EGFR gene respond to the therapy [9]. The gene discussed is EGFR; the disease is lung carcinoma.